Core Scientific shareholders balk at terms of CoreWeave merger offer, FT reports

CoreWeave's proposed $9 billion all-stock acquisition of data center operator Core Scientific is facing significant shareholder opposition, with top Core Scientific investors reportedly planning to vote against the deal unless terms are revised due to perceived undervaluation. This resistance underscores the complexities and valuation challenges in consolidating critical data center and energy capacity amidst the surging demand for AI infrastructure.

Analysis

CoreWeave's proposed $9 billion all-stock acquisition of Core Scientific (CORZ) is facing material risk due to significant opposition from key shareholders. According to reports, major investors in Core Scientific intend to vote against the deal, citing that the current terms undervalue the company. This follows a previously rejected, unsolicited offer from CoreWeave in June 2024, which was also deemed to undervalue the business. The conflict highlights the intense strategic importance and valuation challenges of data center assets amid the surging demand for AI infrastructure, which requires immense energy and computing capacity. With a shareholder vote expected in the autumn, the situation creates a period of uncertainty, reflected in the negative sentiment scores for both Core Scientific (-0.6) and CoreWeave (-0.6). The outcome will be a critical indicator of valuation benchmarks for essential AI infrastructure providers.

Key Decisions for Investors

• Investors in Core Scientific (CORZ) should monitor for a potential revised offer from CoreWeave, as the current shareholder dissent introduces significant deal risk and price volatility.
• The potential for a sweetened bid presents an opportunity for upside, but the risk of the deal collapsing entirely could exert downward pressure on CORZ's valuation.
• This event signals robust M&A interest and potential for valuation re-ratings across the data center sector, warranting a review of other publicly-traded data center operators as potential targets or beneficiaries of higher industry valuations.